Loading…
SCLX
Scilex Holding Co
NASDAQ· Healthcare· Drug Manufacturers - General· CUSIP 80880W205
$4.49-8.18%Price as of Sep 28, 20:02 UTC · updated once a day, after the close
Key metrics
- Market cap
- $31.59M
- P/E
- —
- Forward P/E
- 6.2x
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$49.73
- ROE
- —
- Profit margin
- 0.00%
- Revenue growth
- -22.80%
- Beta
- 1.72
- 52-week high
- $18.58
- 52-week low
- $2.62
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -97.8% over 5Y.
today you would have $22.44▼ -97.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $7.60 | $9.28 | $44.46 | $86.96 | |
| P/S | 2.2x | 1.8x | 0.9x | 2.7x | 9.2x |
| P/B | — | — | — | — | 9.7x |
| EPS | -$36.48 | -$8.05 | -$44.80 | -$5.95 | |
| Profit margin | -186.63% | -1185.78% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MIRAMIRA Pharmaceuticals Inc | $0.75 | — | 3.9x | — | -217.12% | $31.52M |
| NNVCNanoviricides Inc | $1.24 | — | 2.9x | — | -89.97% | $31.65M |
| ATNMActinium Pharmaceuticals, Inc. | $1.01 | 2.9x | 1.0x | — | 45.86% | $31.69M |
| TELATELA Bio, Inc. | $0.70 |
About the company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
- 34
- Palo Alto, United States
Company description provided by Yahoo Finance.